fentanyl has been researched along with Polycystic Ovary Syndrome in 1 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berent-Spillson, A | 1 |
| Love, T | 1 |
| Pop-Busui, R | 1 |
| Sowers, M | 1 |
| Persad, CC | 1 |
| Pennington, KP | 1 |
| Eyvazaddeh, AD | 1 |
| Padmanabhan, V | 1 |
| Zubieta, JK | 1 |
| Smith, YR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Influence of Insulin Resistance on Cognitive, Emotional and Opioid System Functioning in Women With Polycystic Ovary Syndrome[NCT00670800] | 14 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Mu-opioid binding potential in left amygdala measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)" (NCT00670800)
Timeframe: Baseline and after 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 2.28 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 2.08 |
| Normal Controls | 2.03 |
"Mu-opioid binding potential in left nucleus accumbens is measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)~Control group was measured at baseline only." (NCT00670800)
Timeframe: Baseline and after 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 1.95 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 1.65 |
| Normal Controls | 1.53 |
"Mu-opioid binding potential in right amygdala measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)~Control group was measured at baseline only." (NCT00670800)
Timeframe: Baseline and 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 2.28 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 2.11 |
| Normal Controls | 2.06 |
"Mu-opioid binding potential in right nucleus accumbens measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)~Control group was measured at baseline only." (NCT00670800)
Timeframe: Baseline and after 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 2.40 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 2.11 |
| Normal Control Women | 2.05 |
1 other study available for fentanyl and Polycystic Ovary Syndrome
| Article | Year |
|---|---|
Insulin resistance influences central opioid activity in polycystic ovary syndrome.
Topics: Adult; beta-Endorphin; Binding Sites; Brain; Carbon Radioisotopes; Case-Control Studies; Female; Fen | 2011 |